Armis Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Armis Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-560	Closed	-$243K	–	433
2025 Q3	$243K	Buy	+560	New	+$228K	0.02%	280

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Armis Advisers's ALNY Position: Q4 2025 in Review

Armis Advisers sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 560 shares — an estimated $243K sold.

Armis Advisers first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $243K in Q3 2025. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Armis Advisers reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Armis Advisers sold 560 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $243K.
Armis Advisers first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Armis Advisers's Alnylam Pharmaceuticals position peaked at $243K in Q3 2025.
848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Armis Advisers's 13F filing for Q4 2025, filed 24 Mar 2026.